Canopy Growth’s (NYSE:CGC,TSX:WEED) board has dismissed Bruce Linton, co-founder and co-CEO of the Canadian cannabis producer, as its leading executive.

On Wednesday (July 3) the Canadian cannabis producer confirmed Linton would be departing the company effective immediately.

Fellow Canopy Growth co-CEO Mark Zekulin will become the sole CEO for the firm. However, he will participate in the search for new leadership.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

In an interview with Squawk Box, Linton confirmed he did not step down from the firm but instead was terminated.

The now departing executive said once Canopy Growth closed on the second investment injection worth C$5 billion from Constellation Brands (NYSE:STZ) last August, a condition was set for the board to be reconfigured. The New York-based alcohol company currently holds a 38 percent stake in Canopy Growth.

“I think the board had decided they wanted a different chair and a different co-CEO,” Linton said during a televised interview. “So I’m out effective immediately and there’s a search to replace the transitioning co-CEO.”

Despite termination, Linton shows support for Canopy Growth

Under Linton’s tenure, Canopy grew from the first publicly traded marijuana company in Canada to obtain a New York Stock Exchange listing and having a current market valuation of C$18.45 billion.

In a statement, Linton said that, while his turn at the company was over, he was confident in the team replacing him.

“I personally remain committed to a successful transition over the coming year as we begin a process to identify new leadership that will drive our collective vision forward,” Zekulin said in a statement.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Canopy Growth’s biggest investor disappointed with results

Following its blockbuster investment deal into Canopy Growth in November 2017, beverage maker Constellation Brands gained its stake and allowed the marijuana firm to head out and seek a variety of acquisitions with the cash injections it received.

During a quarterly earnings call in June with analysts and investors, Bill Newlands, CEO of Constellation Brands, said his firm was disappointed in the recent quarterly results from Canopy Growth.

As part of its own quarterly results, Constellation Brands indicated that losses tied to the stake in Canopy Growth reached US$106 million on a reported basis, according to a report from the Canadian Press.

“While we remain happy with our investment in the cannabis space and its long-term potential, we were not pleased with Canopy’s recent reported year-end results,” Newlands said.

“However, we continue to aggressively support Canopy on a more focused, long-term strategy to win markets and form factors that matter while paving a clear path to profitability.”

Canopy posted a significant increase in revenues thanks to legalization, but its expansion plans did not help for the bottom line results.

The Canadian producer reported a net loss for Q4 2019 of C$323.3 million for the quarter, resulting in a net loss per share of C$0.98. Over the whole fiscal year, the company posted a net loss of C$685.4 million, indicating a net loss per share of C$2.57.

Canopy also reported an earnings before interest, tax, depreciation and amortization (EBITDA) loss of C$257 million in fiscal 2019, attributed to the investments of the company. The EBITDA loss for the company in fiscal 2018 was C$36.1 million.

Despite an early drop, shares of Canopy Growth quickly saw a marginal rise in Toronto on Wednesday. As of 1:37 p.m. EDT, the firm’s stock was up 1.73 percent to a price of C$53.40.

In New York, the company closed the half trading day—due to the Fourth of July holiday—with a 2.45 percent boost for a price of US$41.06 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.

The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.

Keep reading... Show less

A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.

Meanwhile, a cannabis retail operator elected to celebrate 420 by auctioning a cannabis-themed digital art piece using blockchain technology.

Keep reading... Show less

Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.

Keep reading... Show less

Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola

The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).

Keep reading... Show less